Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/valsartan - Novartis

Drug Profile

Amlodipine/valsartan - Novartis

Alternative Names: Amlodipine besilate/valsartan; Amlodipine besylate/valsartan; Dafiro; Exforge; EXPO-G-Tab; VAA489; Valsartan/amlodipine

Latest Information Update: 28 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Branched-chain amino acids; Dihydropyridines; Ischaemic heart disorder therapies; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 28 Aug 2019 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in South Korea (PO, Tablet)
  • 22 May 2019 Kyung Dong Pharmaceutical completes the phase I KD5001 trial in Hypertension (In volunteers) in South Korea (PO) (KCT0001660)
  • 01 Apr 2015 Generic equivalent available in USA for Hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top